SynthesisFrontiers in oncology2026
Prognostic utility of perineural invasion in individuals with rectal cancer receiving neoadjuvant chemoradiotherapy: a meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to systematically examine the prognostic role of post-neoadjuvant chemoradiotherapy (nCRT) perineural invasion (yPNI) in patients with locally advanced rectal cancer (LARC) treated with nCRT. Methods: This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP Chinese Science and Technology Journal Database (VIP), and Chinese Biomedical Literature Database (SinoMed) were searched to identify eligible studies. Cohort studies that satisfied the inclusion criteria were included, and multivariable-adjusted effect sizes were extracted. The Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of studies. Meta-analyses were carried out using STATA 15.1. Results: A total of 36 studies involving 18,721 patients were included. The pooled prevalence of yPNI was 15.9%. Pooled results showed that yPNI was significantly associated with poorer overall survival (OS) (hazard ratio (HR) = 1.90, 95% confidence interval (CI): 1.63-2.21), recurrence-free survival (RFS) (HR = 1.96, 95% CI: 1.50-2.56), disease-free survival (DFS) (HR = 1.93, 95% CI: 1.55-2.42), cancer-specific survival (CSS) (HR = 1.98, 95% CI: 1.66-2.36), local recurrence-free survival (LRFS) (HR = 2.54, 95% CI: 1.86-3.48), and metastasis-free survival (MeFS) (HR = 2.82, 95% CI: 1.56-5.10). These findings suggested that yPNI-positive patients had a higher risk of recurrence and death. Sensitivity analyses further validated the robustness of the findings. Conclusion: yPNI was associated with adverse survival outcomes in patients with LARC treated with nCRT. Further studies are needed to determine whether yPNI provides additional prognostic information beyond established clinicopathological factors. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251230519, identifier CRD420251230519.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.